CSI Market
Sign In | Register

Sorrento Therapeutics Inc (SRNEQ) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SRNEQ Annual Cash Flow →
Reviewing cash flow figures over time highlights how Sorrento Therapeutics Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income-263.06
Depreciation & amortization7.22
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.32
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation33.48
Income (Loss) from Equity Method Investments0.37
Financial Instruments and Foreign Currency Transaction1.22
Deferred Revenue Period Increase Decrease-
Change In Unrealized Gain Loss On Marketable Securities-
Receipt Of Cost Method Investment For Deferred Revenue-
Contributions To Equity Method Investments-
Marketable Securities Gain Loss-
Gain On Sale Of Marketable Securities-
Derivative Gain Loss On Derivative Net1.30
Gain On Marketable Securities-
Derivative Gain On Derivative-
Noncash Investment In Cost Method Investment-
Available For Sale Securities Gross Realized Gain Loss Net-
Trading Securities Realized Gain Loss Adjustments-
Operating Lease Right Of Use Asset Amortization-
Operating Lease Right Of Use Asset Amortization Expense3.43
Payment Notes Attributed To Accreted Interest Related To Debt Discount-
Impairment Of In Process Research And Development-
Debtor In Possession Facility Upfront Lender Fees And Debt Issuance Costs4.04
Debtor In Possession Facility Exit Fees5.25
Increase Decrease On Contingent Consideration3.80
Current Income Taxes-
Income taxes-0.35
Gain (Loss) on Investments15.46
Accounts Receivable-9.16
Increase (Decrease) in Accounts Payable25.14
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities35.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.16
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities27.31
Discontinued operations0.00
Net Cash flow from Operating Activities-105.12
Investing Activities
Capital Expenditures-0.23
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Asset Acquisitions-
Payments Related To License Agreements-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments1.77
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities1.54
Financing Activities
Short-term debt Net6.86
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-5.29
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock21.53
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net49.56
Payments For Repurchase Of Common Stock For Deferred Compensation Obligations-
Proceeds From Repayments Of Long Term Debt-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Restricted Cash-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Proceeds From Issuance Of Senior Long Term Debt Net Of Issuance Costs-
Other Significant Noncash Transaction Value Of Consideration Given-
Payments Related To Share Exchange-
A C E A Acquisition Consideration Paid In Equity-
Other Acquisitions License Agreements And Investments Paid In Equity-
Capital Expenditures Incurred But Not Yet Paid6.39
Noncash Or Part Noncash Short Term Debt-
Proceeds From Debtor In Possession Facility Net Of Lender Fees And Debt Issuance Cost70.96
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid-0.01
Net Cash Flow from Financing Activities150.01
Effect of exchange rate on cash flow-0.32
Discontinued operations0.00
Free Cash Flow-105.34
Total Cash Flow46.44
4 historic quarters locked

Sign in to unlock the full Sorrento Therapeutics Inc cash flow history.

Sign In Create Free Account

About Sorrento Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-041995

Figures are derived from filed reports and may be restated. Historical data is subject to revision.